NASDAQ · SIBN

SI – BONE, Inc.

$17.05 +$0.43 (+2.59%) 1D After hours

Key Metrics

$737.09M
Market cap
P/E · TTM
$206.22M
Revenue · TTM
−$16.70M
Net income
EPS · TTM $-0.39
Dividend yield
Free cash flow −$5.55M
Beta · 1Y 0.77
EBITDA · TTM −$13.83M
Gross margin 79.6%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 12
    The stock moved +19.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 12
  • May 11
    From its Jan 30 high, the share price fell 30%.

    Peak close $16.58 on Jan 30; trough close $11.61 on May 11. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -30%
  • Apr 13
    The stock moved +9.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 13

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$737.09M
Enterprise value$739.15M
Shares outstanding44.3M
52-wk range$11.48 – $21.89
Avg volume · 20D376.9K
Net cash −$2.06M
Book value / share$4.23
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About SI – BONE, Inc.
IPO dateOct 17, 2018
Employees376

SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S3.57
P/FCF
EV/EBITDA
EV/Sales3.58
Graham №

Profitability

Gross 79.6%
Operating -9.7%
Net -8.1%
FCF -2.7%
ROE / ROIC -9.7% · —

Financial Health

Current ratio9.99
Quick ratio8.34
Debt / equity0.20
Debt / EBITDA -2.57
Net cash −$2.06M
Working capital$193.23M

Cash Flow · TTM

Operating CF $1.87M
Capex −$7.42M
Free cash flow −$5.55M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

5.8
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings